Literature DB >> 16208531

Relationship and prognostic significance of phospho-(serine 166)-murine double minute 2 and Akt activation in node-negative breast cancer with regard to p53 expression.

K J Schmitz1, F Grabellus, R Callies, J Wohlschlaeger, F Otterbach, R Kimmig, B Levkau, K W Schmid, H A Baba.   

Abstract

The Akt signalling pathway plays a central role in tumourigenesis. Activation of Akt is related to a more aggressive phenotype in various human cancers, including breast cancer. Its activation contributes to cancer progression via pleiotropic effects, including suppression of apoptosis and modulation of cell cycle regulation. Murine double minute 2 (MDM2) is an oncoprotein that inhibits the function of p53 tumour suppressor protein. Cell culture studies show that Akt-related phosphorylation of MDM2 at serine 166 allows MDM2 to gain nuclear entry and fulfil its p53 regulating function. This study was designed to analyse the relationship of phospho-MDM2 (pMDM2) expression with Akt activation to determine a possible prognostic relevance of pMDM2 in node-negative breast cancer with respect to Akt activation and p53 status. pMDM2, phospho-Akt (pAkt) and p53 protein expression status were analysed immunohistochemically in 121 paraffin-embedded breast cancer cases. Expression of pMDM2 correlated with Akt activation (P<0.001). Univariate analysis identified pMDM2 as a prognostic factor (P=0.0458) in node-negative breast cancers. The unfavourable prognostic significance was even more pronounced in tumours with a pMDM2(+)/pAkt(+) immunophenotype (P=0.0205). Stratification into a p53-negative subgroup further strengthened the adverse prognostic influence. These data confirm that MDM2 phosphorylation at serine 166 is mediated by Akt kinase. Besides the prognostic impact of pMDM2, our findings suggest that Akt-mediated modulation of the MDM2/p53 complex contributes to increased tumour aggressiveness especially in p53-negative breast cancers. However, due to the relatively small number of patients in this cohort, the results obtained need to be confirmed by larger cohorts.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16208531     DOI: 10.1007/s00428-005-0086-0

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  31 in total

1.  Phosphoinositide 3-OH kinase (PI3K) and PKB/Akt delay the onset of p53-mediated, transcriptionally dependent apoptosis.

Authors:  P Sabbatini; F McCormick
Journal:  J Biol Chem       Date:  1999-08-20       Impact factor: 5.157

Review 2.  Oncogenic kinase signalling.

Authors:  P Blume-Jensen; T Hunter
Journal:  Nature       Date:  2001-05-17       Impact factor: 49.962

3.  Mitosis counting--a need for reappraisal.

Authors:  P S Ellis; R Whitehead
Journal:  Hum Pathol       Date:  1981-01       Impact factor: 3.466

4.  Clinical relevance of immunohistochemical expression of p53-targeted gene products mdm-2, p21 and bcl-2 in breast carcinoma.

Authors:  A Bánkfalvi; K Tory; M Kemper; D Breukelmann; C Cubick; C Poremba; L Füzesi; R J Lellè; W Böcker
Journal:  Pathol Res Pract       Date:  2000       Impact factor: 3.250

5.  Overexpression of MDM2 oncoprotein correlates with possession of estrogen receptor alpha and lack of MDM2 mRNA splice variants in human breast cancer.

Authors:  Masao Hori; Jiro Shimazaki; Satoshi Inagawa; Masayuki Itabashi; Mitsuo Hori
Journal:  Breast Cancer Res Treat       Date:  2002-01       Impact factor: 4.872

6.  PKB/Akt mediates cell-cycle progression by phosphorylation of p27(Kip1) at threonine 157 and modulation of its cellular localization.

Authors:  Incheol Shin; F Michael Yakes; Federico Rojo; Nah-Young Shin; Andrei V Bakin; Jose Baselga; Carlos L Arteaga
Journal:  Nat Med       Date:  2002-09-16       Impact factor: 53.440

7.  mdm2 gene alterations and mdm2 protein expression in breast carcinomas.

Authors:  A Marchetti; F Buttitta; S Girlando; P Dalla Palma; S Pellegrini; P Fina; C Doglioni; G Bevilacqua; M Barbareschi
Journal:  J Pathol       Date:  1995-01       Impact factor: 7.996

Review 8.  MDM2 and prognosis.

Authors:  Kenan Onel; Carlos Cordon-Cardo
Journal:  Mol Cancer Res       Date:  2004-01       Impact factor: 5.852

Review 9.  The MDM2 gene amplification database.

Authors:  J Momand; D Jung; S Wilczynski; J Niland
Journal:  Nucleic Acids Res       Date:  1998-08-01       Impact factor: 16.971

10.  Stabilization of Mdm2 via decreased ubiquitination is mediated by protein kinase B/Akt-dependent phosphorylation.

Authors:  Jianhua Feng; Rastislav Tamaskovic; Zhongzhou Yang; Derek P Brazil; Adrian Merlo; Daniel Hess; Brian A Hemmings
Journal:  J Biol Chem       Date:  2004-05-28       Impact factor: 5.157

View more
  4 in total

1.  Collateral-resistance to estrogen and HER-activated growth is associated with modified AKT, ERα, and cell-cycle signaling in a breast cancer model.

Authors:  Kate M Moore; Vera Cerqueira; Kenneth G MacLeod; Peter Mullen; Richard L Hayward; Simon Green; David J Harrison; David A Cameron; Simon P Langdon
Journal:  Explor Target Antitumor Ther       Date:  2022-02-28

Review 2.  AKT and ERK1/2 signaling in intrahepatic cholangiocarcinoma.

Authors:  K J Schmitz; H Lang; J Wohlschlaeger; G C Sotiropoulos; H Reis; K W Schmid; H A Baba
Journal:  World J Gastroenterol       Date:  2007-12-28       Impact factor: 5.742

3.  A splice variant of HER2 corresponding to Herstatin is expressed in the noncancerous breast and in breast carcinomas.

Authors:  Triantafyllia Koletsa; Ioannis Kostopoulos; Elpida Charalambous; Barbara Christoforidou; Eleni Nenopoulou; Vassiliki Kotoula
Journal:  Neoplasia       Date:  2008-07       Impact factor: 5.715

4.  Dietary Supplementation of Vitamin E and α-Lipoic Acid Upregulates Cell Growth and Signaling Genes in Rat Myocardium.

Authors:  Susan A Marsh; Steven Mason; Leigh C Ward; Jeff S Coombes
Journal:  Int J Biomed Sci       Date:  2006-12
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.